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OAR dose constraintsa b s t r a c t
Purpose: Quality assessment of the treatment plans in the Danish Breast Cancer Group (DBCG) HYPO trial
was carried out based on prospectively reported dosimetric parameters and evidence-based dose con-
straints for whole breast radiation therapy were derived.
Materials and methods: From 2009 to 2014, 1882 patients (pts) were randomised between
50 Gy/25fractions (fr) versus 40 Gy/15fr. Doses to CTVp_breast (V95%, V107%-V110%, Dmax, and in addition
for 40 Gy plans V105%-V107%), ipsilateral lung (V20Gy/V17Gy), heart (V20Gy/V17Gy, V40Gy/V35Gy), and left ante-
rior descending coronary artery (LADCA) (Dmax) and use of respiratory gated technique were prospec-
tively reported to the DBCG database. After end of accrual, these dosimetric parameters from all plans
in the trial were compared to the pre-specified treatment constraints.
Results: In total, 1854 pts from eight radiation therapy (RT) centres in three countries were treated. No
statistically significant differences were found between the results for 40 Gy and 50 Gy plans, except
for CTVp_breast hot-spot volume (V107%-V110%). Of the 40 Gy pts, 90% with CTVp_breast > 600 mL and
95% with CTVp_breast  600 mL had a CTVp_breast hot-spot volume (V105%-V107%) <2%. In 95% of the
50 Gy plans, the CTVp_breast absolute hot-spot volume (V107%-V110%) was <0.5 mL and 1.7 mL for
CTVp_breast  600 mL and > 600 mL, respectively. Compliance was >99% for both heart and lung con-
straints. Largest deviation from protocol constraints was found for the volume of CTVp_breast covered
with 95% of the prescription dose or more (V95%). The CTV dose coverage (V95%) was >94.3% in 95% of
the right-sided pts, whereas the figures for 95% of the left-sided pts treated with and without respiratory
gating were 93.2% and 88.8%, respectively.
Conclusion: A high degree of compliance with protocol dose constraints was found for treatment plans in
the DBCG HYPO trial. New constraints for dose to organs at risk and high-dose volumes in the breast are
suggested for breast-only RT planning.
 2021 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
For decades, the standard fractionation for radiation therapy
(RT) after breast conserving surgery was 50 Gy/25fractions (fr),
because early experience with moderately hypofractionated breast
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[1,2]. Since then, 3D CT-based treatment planning has emerged.
Furthermore, the a/b ratio for late normal tissue changes in the
breast has been reported to be around 3 Gy, supporting modest
increase to fraction size above 2 Gy [3]. Such schedules were tested
in randomised trials in Canada and the UK. The Canadian trial
tested 42.5 Gy/16fr versus 50 Gy/25fr [4], whereas the UK START
Trial B tested 40 Gy/15fr/3weeks versus 50 Gy/25fr/5weeks [5,6].
The favourable results from these trials paved the way for more
widespread use of moderate hypofractionation for breast RT.
After the initial encouraging results from the START Trial B [5],
the Danish Breast Cancer Group (DBCG) RT Committee decided to
reintroduce moderately hypofractionated RT through a clinically
controlled randomised trial, including patients with an indication
for breast-only RT. The fractionation design of the DBCG HYPO trial
was similar to the START Trial B, however with an additional con-
straint for breast doses in the range of 105% to 107% of the pre-
scription dose in the 40 Gy arm compared to the 50 Gy arm. The
primary endpoint in the DBCG HYPO trial was 3-year breast
induration grade 2–3.
A quality assessment (QA) program was set up to ensure that
the technical guidelines were followed in the participating centres
(4 in Denmark, 2 in Norway and 2 in Germany). For each individual
treatment plan, a selection of dosimetric parameters were prospec-
tively reported to the DBCG database. After end of accrual, analysis
of these parameters evaluated the compliance of the participating
centers with the trial protocol. Recently, the first results from the
trial were reported with median 7.3-year follow-up. The nine-
year loco-regional recurrence risks in the DBCG HYPO study were
3.3% (95% Cl, 2.0% to 5.0%) and 3.0% (95% Cl, 1.9% to 4.5%) in the
50 Gy and 40 Gy arm, respectively, and radiation-associated car-
diac and lung disease was seldom [7]. This supported that the dose
constraints applied for the treatment planning in this study were
appropriate, and the dosimetric results from the study may be used
to improve the constraints for future planning.2. Materials and methods
Patients older than 40 years with a T1-2 N0-N1(mic) invasive
adenocarcinoma or ductal carcinoma in situ (DCIS) referred to
postoperative whole breast RT were eligible for inclusion in the
DBCG HYPO trial. No RT of regional nodes was allowed. Stratifica-
tion factors were breast size (smaller/larger than 600 mL), boost
(yes/no), systemic treatment and institution. The patients were
randomized to whole breast irradiation 50 Gy/25fr/5weeks versus
40 Gy/15fr/3weeks. Boost was prescribed as sequential 5–8 fr of
2 Gy according to national or institutional guidelines (supplemen-
tary material in [7]). A written informed consent according to Good
Clinical Practice guidelines and local and national rules of partici-
pating institutions was obtained. The trial was approved by the
Ethics Committee in Region Midt, Denmark, on behalf of all partic-
ipating Danish centres, and by local Ethics Committees for the non-
Danish centres (clinicaltrials.gov number NCT00909818).2.1. Planning CT scanning
Treatment preparation was according to DBCG RT guidelines.
The neck and breast region including both lungs was CT scanned
with the patient positioned in the institutional standard fixation
for this patient group. The only requirement was that a daily repro-
ducibility of approx. 5 mm should be achieved during the course of
treatment. The institutional guideline for respiratory gating and
image verification were followed and had to be identical for the
two treatment arms..1192.2. Delineation of target volumes and organs at risk
The CTVp_breast was defined according to DBCG guidelines,
which was identical to the ESTRO guidelines [8,9]. CTVp_boost
was defined as a 5 mm expansion from the volume including sur-
gical clips and a relevant part of the surgical cavity guided by pre-
surgical imaging and the surgical report, and cropped inside the
CTVp_breast. PTVs were constructed from the CTVs following the
institutional standard CTV-PTV margins for whole breast RT, and
cropped to 5 mm below the skin. Heart, ipsilateral lung and con-
tralateral breast were defined as organs at risk (OAR) [10].
2.3. Treatment planning
The recommended treatment technique was a one-isocenter
technique with two tangential fields with parallel posterior field
borders. Wedges or field-in-field segments were applied to obtain
a homogeneous dose distribution. However, inverse optimized
IMRT planning was also an option. The institutional dose calcula-
tion algorithm was used. There was no restriction on the photon
energy used except that the 95% isodose curve should cover the
breast 5 mm below the surface. The CTVp_breast was to be covered
with doses in the range 95%-105% (40 Gy plans) and 95%-107%
(50 Gy plans) of the prescription dose and Dmax  110%. For the
40 Gy arm, a volume of up to 2% of the CTVp_breast could receive
a dose between 105% and 107% of the prescription dose
(V105%-V107%2%). In both treatment arms, an absolute volume of
the CTVp_breast of up to 2 mL could receive a dose in the range
107%-110% of the prescription dose (V107%-V110%<2mL). In this
way, hot spots in the breast were defined for doses >105% for
40 Gy plans and >107% for 50 Gy plans, respectively. No part of
the CTVp_breast except for build-up regions should be covered
with doses <95% of the prescription dose (V95%95%), correspond-
ing to under-dosed volumes.
The maximum dose to <25% of the ipsilateral lung was 20 Gy
(50 Gy plans) and 17 Gy (40 Gy plans) (V20Gy/V17Gy  25%). <10%
and 5% of the heart should receive 20 Gy and 40 Gy, respectively,
in 50 Gy plans and 17 Gy and 35 Gy, respectively, in 40 Gy plans
(V20Gy/V17Gy  10% and V40Gy/V35Gy  5%). Delineation of the left
anterior descending coronary artery (LADCA) and contralateral
breast was optional. If LADCA was delineated, DLADCA,max was
17 Gy and 20 Gy in 40 Gy and 50 Gy plans, respectively. The dose
to the contralateral breast should be as low as possible. It is note-
worthy that the constraints for 50 Gy/25fr were all based on con-
sensus (in lack of evidence) in the DBCG RT Committee dating
back to the days where CT-based RT planning was introduced.
The committee was worried about excess morbidity after
hypofractionated RT, so the constraints were deliberately stricter
for the 40 Gy plans. Highest priority was given to CTVp_boost or
tumor bed if no boost, thereafter the priority was
heart > ipsilateral lung > CTVp_breast > PTVp_breast > contralatera
l breast, however, every treatment plan was to be balanced and
approved after considering information about the patient, comor-
bitidy, tumour characteristics and other treatment factors.
2.4. Data available for analysis
The dosimetric parameters for CTVp_breast (V95%, V107%-V110%,
Dmax, and in addition for 40 Gy plans V105%-V107%), ipsilateral lung
(V20Gy/V17Gy), heart (V20Gy/V17Gy, V40Gy/V35Gy) and LADCA (Dmax)
were prospectively reported to the DBCG database. Prior to analy-
sis, the data quality was investigated, and if values deviated much
from expected values, the centre was asked to confirm the value.
Use of respiratory gating was added to the database in 2012 [7],
thus, data on gating prior to 2012 was collected retrospectively
from the centres.
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Compliance with the protocol treatment constraints and 50th
(median), 90th, and 95th percentiles for dosimetric parameters
were determined for both treatment arms, and for various sub-
groups of patients according to laterality, use of respiratory gating,
and CTVp_breast volume. Student’s t-test in MS Excel version 2010
was used to test for statistical significance (p < 0.05).3. Results
Between May 2009 and March 2014, 1854 eligible patients
were treated [7]. RT characteristics from their treatment plans
are presented in table 1. Table 2 shows the compliance with the
predefined dose constraints. Data on modified treatment plans
was reported for 5 pts (0.3%) and of these, 3 pts had a new plan
during the treatment course, whereas the remaining two were
replanned prior to treatment start.
The largest number of deviations from the constraint was found
for the dose coverage (V95%), however, no statistically significant
difference was found between the under-dosed volumes of
CTVp_breast in the 50 Gy and 40 Gy plans (Fig. 1a). The best dose
coverage of CTVp_breast was reported for right-sided patients with
V95%>94.3% in 95% of the plans, whilst the coverage in left-sided
gated patients was significantly less with V95%>93.2% (p < 0.001),
and even worse for left-sided patients treated in free breathing
(FB), where V95%>88.8% (p < 0.001) (Fig. 1a). In the 40 Gy treatment
arm, non-compliance to the constraint V105%-V107%2% was found
in 68 treatment plans of which 47 and 21 patients had large
(CTVp_breast > 600 mL) and small breasts (CTVp_breast 600 mL),Table 1
Characteristics of the 1854 patients treated in the DBCG HYPO trial.
Fractionation schedule
50 Gy 40 Gy Total
Number of patients (n) 937 917 1854










Right (n) 455 445 900
Left (n) 482 472 954
Gating (left-sided patients) (n)
Yes 231 226 457
No 251 246 497
Boost (n)
No 721 703 1424
10 Gy/5 fr 183 185 368
16 Gy/8 fr 33 29 62
Table 2
Compliance with dose constraints in the DBCG HYPO trial for volume of CTVp_breast receivi
plans) and 107–110% of prescription dose (V105%-V107%, V107%-V110%), maximum dose to CT
(40 Gy plans) (V20Gy/V17Gy), heart receiving 40 Gy (50 Gy plans) or 35 Gy (40 Gy plans) (V
50 Gy
Protocol constraint Compliance Non compliance
V95%  95% 767 (81.9%) 166 (17.7%)
V105%-V107% 2% – –
V107%-V110% <2cm3 899 (95.9%) 35 (3.7%)
Dmax  110% 927 (98.9%) 7 (0.7%)
Lung V20Gy/V17Gy  25% 924 (98.6%) 8 (0.9%)
Heart V20Gy/V17Gy  10% Right 431 (94.7%) 0 (0.0%)
Left 480 (99.6%) 0 (0.0%)
Heart V40Gy/V35Gy  5% Right 431 (94.7%) 0 (0.0%)
Left 480 (99.6%) 0 (0.0%)
LADCA Dmax  20 Gy/17 Gy Right 404 (88.8%) 0 (0.0%)
Left 411 (85.3%) 29 (6.0%)
120respectively, corresponding to 90% of the large-breasted and 95% of
the small-breasted patients having treatment plans with a
CTVp_breast hot-spot volume (V105% -V107%) up to 2% (Fig. 1b). Lar-
ger breast hot-spot volumes were observed in 50 Gy plans com-
pared to 40 Gy plans (p = 0.001) as 2.1% (small breasts) and 4.7%
(large breasts) of the 40 Gy patients received breast doses above
107% of the prescription dose, whereas the corresponding figures
for 50 Gy patients were 9.0% and 14.8% (Fig. 1c). However, in 95%
of the 50 Gy plans the CTVp_breast absolute hot-spot volume
(V107%-V110%) was<0.5 mL and 1.7 mL for small and large breast,
respectively.
For both lung and heart constraints, compliance was > 99%
(table 2). Delineation of the heart was not carried out in 57 (6%)
of the right-sided patients, whereas data was missing for only
three left-sided patients. Since it was optional to delineate LADCA,
a higher number of missing data was expected for LADCA. For ipsi-
lateral lung, the highest lung V20Gy/17Gy values were seen for right-
sided patients, followed by FB and gated left-sided patients,
respectively (Fig. 2a). No statistically significant difference was
found between the lung values for 40 Gy plans and 50 Gy plans
with p = 0.50 (right), p = 0.06 (left, gated), and p = 0.53 (left, FB).
The heart data are shown in Fig. 2b and c. Also, for the heart no sta-
tistically significant difference was found when comparing 40 Gy
plans and 50 Gy plans with p-values for V20Gy/17Gy of 0.31 (right),
0.27 (left, gated) and 0.80 (left, FB) and corresponding values for
V40Gy/35Gy of 0.25, 0.38, and 0.16. Table 3 summarizes the 50th
(median), 90th, and 95th percentiles for lung, heart and breast
dosimetric parameters.4. Discussion
This paper presents dosimetric parameters from the individual
CT-based treatment plans of all patients treated in the DBCG HYPO
trial. Compliance with the pre-defined dose constraints was high
for all prospectively reported parameters, except the under-
dosed volume of CTVp_breast (1-V95%). For 95% of the right-sided
patients, CTVp_breast V95% was>94.3% whereas the corresponding
values for left-sided patients were 93.2% (gated) and 88.8% (FB),
showing that the heart constraints had higher priority in the pro-
tocol than CTVp_breast coverage. This reflects the focus on the risk
of late cardiac morbidity in this group of early breast cancer
patients [11–13] and a recent analysis of cardiac substructures in
the Danish HYPO cohort showed decreasing mean heart and
LADCA doses with treatment year [14]. However, the excellent
clinical results obtained in this study with nine-year loco-
regional recurrence risks of 3.3% (95% Cl, 2.0% to 5.0%) for the
50 Gy arm and 3.0% (95% Cl, 1.9% to 4.5%) for the 40 Gy arm indi-
cate that this trade-off was feasible [7]. No statistically significantng>95% of prescription dose (V95%), volume of CTVp_breast receiving 105–107% (40 Gy
Vp_breast (Dmax), volumes of lung and heart receiving 20 Gy (50 Gy plans) or 17 Gy
40Gy/V35Gy), and maximum dose to left anterior descending coronary artery (LADCA).
40 Gy
Missing data Compliance Non compliance Missing data
4 (0.4%) 730 (79.6%) 185 (20.2%) 2 (0.2%)
– 846 (92.3%) 68 (7.4%) 3 (0.3%)
3 (0.3%) 907 (98.9%) 9 (1.0%) 1 (0.1%)
3 (0.3%) 911 (99.3%) 5 (0.5%) 1 (0.1%)
5 (0.5%) 912 (99.5%) 3 (0.3%) 2 (0.2%)
24 (5.3%) 412 (92.6%) 0 (0.0%) 33 (7.4%)
2 (0.4%) 470 (99.6%) 1 (0.2%) 1 (0.2%)
24 (5.3%) 412 (92.6%) 0 (0.0%) 33 (7.4%)
2 (0.4%) 470 (99.6%) 1 (0.2%) 1 (0.2%)
51 (11.2%) 395 (88.8%) 0 (0.0%) 50 (11.2%)
42 (8.7%) 382 (79.3%) 47 (9.8%) 43 (8.9%)
Fig. 1. a: Volume of CTVp_breast covered with 95% of prescription dose (V95%), b:
Volume of CTVp_breast with a hot spot dose between 105% and 107% of the
prescription dose (V105%-V107%) for 40 Gy plans, and c: Volume of CTVp_breast with
a hot spot dose between 107% and 110% of the prescription dose (V107%-V110%) for
both 40 Gy and 50 Gy plans versus percentile of patients. In b and c results are
shown for patients with a CTVp_breast smaller than or equal to 600 mL and
CTVp_breast>600 mL. Constraints are shown with horizontal dashed-dotted lines,
whereas the vertical lines show the 90th (solid line) and 95th (dashed line)
percentiles. In c, two (27.0 and 48.6 mL) and one (24.3 mL) data points are outside
the scale for CTVp_breast > 600 mL (50 Gy plans) and CTVp_breast > 600 mL (40 Gy
plans), respectively.
Fig. 2. a. Lung V20Gy (50 Gy plans) and V17Gy (40 Gy plans) b. Heart V20Gy (50 Gy
plans) and V17Gy (40 Gy plans), and c. Heart V40Gy (50 Gy plans) and V35Gy (40 Gy
plans) versus percentile of patients. The constraints in the trial protocol are shown
with horizontal dashed-dotted lines, whereas the vertical lines show the 90th (solid
line) and 95th (dashed line) percentiles.
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plans except for CTVp_breast hot-spot volume (V107%-V110%).
The statistically significant larger proportion of 50 Gy patients
with a higher hot-spot breast volume compared to 40 Gy patients
was a result of the additional dose constraint of V105%-V107%2% for
40 Gy plans. As the patients in the two arms had similar breast
sizes, it was expected, that more 50 Gy plans could have had a
smaller hot-spot volume if the additional 40 Gy hot-spot constraint
had been applied to the 50 Gy patients. The lower hot spot volumes
for 40 Gy patients may be due to the use of a higher proportion of121high energy photon beam in the treatment plan, thereby increasing
the build-up zone in the breast. However, this was not reflected in
the under-dosed volumes of CTVp_breast, where no statistically
significant difference was observed between the 50 Gy and 40 Gy
plans. Thus, the hot-spot constraint V105%-V107%2% used in the
protocol is recommended as a hot-spot constraint for whole breast
RT plans in the future.
From a clinical perspective, no patients were hospitalized with
radiation pneumonitis in the DBCG HYPO trial, and only very few
patients had died from heart or lung disease with no indication
of an excess risk [7]. For the lung and heart, the 95th percentile val-
ues for lung and heart presented in table 3 are therefore suggested
as new OAR constraints for whole-breast RT planning. These con-
straints are to our knowledge the first constraints for doses to
OAR based on dosimetric data collected from all treatment plans
in a randomized trial, and they represent constraints depending
on laterality and use of respiratory gated technique.
Table 3
50th (median), 90th, and 95th percentile values for lung V20Gy/V17Gy, heart V20Gy/V17Gy and V40Gy/V35Gy, and volume of CTVp_breast covered with 95% of prescription dose (V95%)
for right-sided and left-sided patients treated with respiratory gating and in free breathing, respectively. The same figures are given for volume of CTVp_breast with doses
between 105% and 107% of prescription dose (V105%-V107%) (40 Gy) and between 107% and 110% of prescription dose (V107%-V110%) for 40 Gy plans, 50 Gy plans, and pooled.
Percentile Right Left, gating Left free breathing
Lung V20Gy/V17Gy [%] 50th 16.6 13.5 14.3
90th 22.3 18.3 20.9
95th 23.8 19.6 22.3
Heart V20Gy/V17Gy [%] 50th 0.0 0.1 0.7
90th 0.0 1.1 4.5
95th 0.0 2.0 6.4
Heart V40Gy/V35Gy [%] 50th 0.0 0.0 0.0
90th 0.0 0.1 1.9
95th 0.0 0.4 3.2
CTVp_breast V95% [%] 50th 97.6 97.0 95.5
90th 95.2 94.1 90.4
95th 94.3 93.2 88.8
Percentile 40 Gy/15fx 50 Gy/25fx All
CTVp_breast V105% -V107% [%] 50th 0.0 NA NA
90th 1.8 NA NA
95th 2.7 NA NA
CTVp_breast V107% -V110% [mL] 50th 0.0 0.0 0.0
90th 0.0 0.1 0.0
95th 0.0 1.2 0.3
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constraints was due to the fact that in the treatment planning
the heart had the highest priority after the tumour bed. Shortly
after the end of recruitment in the HYPO trial an initial analysis
of the heart doses from the Danish HYPO patients was presented
to the DBCG RT Committee, and it was decided to change the heart
constraints in the RT guidelines to V35Gy < 1% and V17Gy < 5% for
whole-breast planning. These values may now be reduced even
further by the results presented here. For loco-regional treatment
the corresponding DBCG constraints are  5% and  10%,
respectively.
In accordance with other large trials (IMPORT LOW, FAST, and
FAST Forward), this trial recommended two tangential fields with
field-in-field segments to obtain a homogeneous dose distribution
[5,15,16]. However, 3D CRT forward field-in-field planning can be
tedious. Therefore, several planning studies with a limited number
of patients have investigated alternative field arrangements using
either two inversed planned tangential IMRT fields, IMRT with
more than two fields or volumetric modulated arc therapy (VMAT)
[17–19]. The advantage of a tangential field technique is that irra-
diation of the contralateral side of the patient is minimised. Fur-
thermore, Aznar et al. showed in a systematic review of lung
doses from breast cancer RT that tangential fields spared both
the ipsilateral and contralateral lung better than IMRT for whole
breast RT without nodal irradiation [20]. With breathing adaption,
3D-CRT and tangential IMRT fields also had higher potential for
sparing the heart compared to a partial VMAT technique [21].
These conclusions were recently validated in another study show-
ing that the 3D-CRT in many situations is to be preferred [28].
Formation of fibrosis is dependent on several factors including
hot-spot volumes in the breast [22]. This study has shown that
breast hot-spot volumes also for large breasts can be minimized
with tangential fields. Thus, this technique is far from an outdated
method for whole breast RT.
This report was limited to the dosimetric parameters defined
prior to the start of the trial and manually reported to the DBCG
database. In this way it was possible to collect data from all
patients treated. However, at that time the DBCG RT committee
decided to report values related to CTVp_breast, whereas
PTVp_breast values were not included in the list of manually
reported values. All treatment plans from the Danish centres were122also prospectively collected in a national storage facility of DICOM
data (plan data bank), where values for analysis are not limited to a
pre-defined set. Due to legislation issues at the time of recruit-
ment, it was not possible for the Norwegian and German centres
to export treatment plans to the Danish data bank. Thus, only
results for the predefined and prospectively reported parameters
can be presented for the total number of treatment plans in the
trial.
Brink et al. demonstrated that the data quality in a treatment
plan data bank was superior to manually reported data [23]. There-
fore, quality assurance of the manually entered dosimetric param-
eters was carried out prior to the data analysis. If a dosimetric
value deviated much from the expected range, the responsible
physicist at the centre was asked to confirm the value. Dose cover-
age of the CTVp_breast (V95%) was the dosimetric parameter with
most need of corrections during the data validation, confirming
the findings in [23]. This was probably because the parameter to
be prospectively reported was 1-V95% while the value most easily
read from the treatment planning systems was V95%. Thus, for man-
ually recording and reporting dose values it is recommended to
choose parameters which are easily read from dose volume
histograms.
During the trial period, the fraction of left-sided patients treated
with respiratory gating increased from 7% in 2009–2010 to 85% in
2013–2014, thus in total 457 (48%) of the left-sided patients were
treated with gating, whereas the remaining 497 left-sided patients
were treated in FB. Results from treatment plans for 684 left-sided
Danish patients in the DBCG HYPO trial submitted to the plan data
bank presented by Berg et al were in harmony with other studies
reporting that respiratory gated technique can improve target, lung
and heart dose [24–26]. This was also observed in the complete
data set from this trial. Apart from a lower heart exposure for gated
patients, also lower lung V20Gy/17Gy values were obtained, poten-
tially resulting in a decreased risk of a second lung cancer [27].
In conclusion, the prospectively collected treatment data from
all treated breast cancer patients in the DBCG HYPO trial demon-
strated a high degree of compliance with pre-specified constraints
for treatment planning. This suggests that more strict dose con-
straints for organs at risk and for high dose breast volumes can
be applied and are recommended for future whole breast RT
planning.
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